Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06559891Not ApplicableRecruiting

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

Role: lead

NCT05372679Not ApplicableActive Not Recruiting

REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /

Role: lead

NCT02835950Not ApplicableUnknown

TReatment Of Pulmonary HYpertension 1-US Study

Role: lead

NCT03611270Not ApplicableActive Not Recruiting

TReatment of Pulmonary Hypertension Group II Study

Role: lead

NCT04570228Not ApplicableUnknown

TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal Study

Role: lead

NCT02516722Not ApplicableUnknown

TReatment Of Pulmonary HYpertension 1 Study

Role: lead

All 6 trials loaded